CA3173799A1 - Methods and compositions for treating cancer - Google Patents

Methods and compositions for treating cancer

Info

Publication number
CA3173799A1
CA3173799A1 CA3173799A CA3173799A CA3173799A1 CA 3173799 A1 CA3173799 A1 CA 3173799A1 CA 3173799 A CA3173799 A CA 3173799A CA 3173799 A CA3173799 A CA 3173799A CA 3173799 A1 CA3173799 A1 CA 3173799A1
Authority
CA
Canada
Prior art keywords
cancer
expression
pkmyt1
protein
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3173799A
Other languages
English (en)
French (fr)
Inventor
Stephen Harrison
Christine Taylor Brew
Michael David Winther
Sourabh Banerjee
Shawn YOST
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Engine Biosciences Pte Ltd
Original Assignee
Engine Biosciences Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engine Biosciences Pte Ltd filed Critical Engine Biosciences Pte Ltd
Publication of CA3173799A1 publication Critical patent/CA3173799A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3173799A 2020-04-01 2021-03-31 Methods and compositions for treating cancer Pending CA3173799A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003736P 2020-04-01 2020-04-01
US63/003,736 2020-04-01
PCT/US2021/025230 WO2021202780A2 (en) 2020-04-01 2021-03-31 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
CA3173799A1 true CA3173799A1 (en) 2021-10-07

Family

ID=77927411

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3173799A Pending CA3173799A1 (en) 2020-04-01 2021-03-31 Methods and compositions for treating cancer

Country Status (9)

Country Link
US (1) US20230149415A1 (enExample)
EP (1) EP4127722A4 (enExample)
JP (1) JP2023519931A (enExample)
KR (1) KR20230017167A (enExample)
CN (1) CN115769077A (enExample)
AU (1) AU2021249111A1 (enExample)
CA (1) CA3173799A1 (enExample)
MX (1) MX2022012181A (enExample)
WO (1) WO2021202780A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240398799A1 (en) * 2021-08-19 2024-12-05 Engine Biosciences Pte. Ltd. Compositions and methods for generating synthetic lethality in tumors
WO2023177356A2 (en) * 2022-03-18 2023-09-21 Engine Biosciences Pte. Ltd. Compounds and method for pkmyt1 inhibition
KR20250136774A (ko) * 2024-03-08 2025-09-16 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도
WO2025215187A1 (en) 2024-04-11 2025-10-16 My-T Bio Limited Therapeutic compounds and their use
WO2025215188A1 (en) 2024-04-11 2025-10-16 My-T Bio Limited Therapeutic compounds and their use as inhibitors of pkmyt1
WO2025242880A1 (en) 2024-05-24 2025-11-27 My-T Bio Limited Therapeutic compounds and their use
WO2026057597A1 (en) 2024-09-10 2026-03-19 My-T Bio Limited Pkmyt1 inhibitors and their use
WO2026057598A1 (en) 2024-09-10 2026-03-19 My-T Bio Limited Therapeutic compounds as pkmyt1 inhibitors and their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002607A1 (en) * 2007-05-01 2008-12-31 Dana-Farber Cancer Institute, Inc. Compositions and methods for identifying transforming and tumor suppressor genes
RS56680B1 (sr) * 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
EP3313819A1 (en) * 2015-06-23 2018-05-02 Case Western Reserve University Compositions and methods for treating cancer

Also Published As

Publication number Publication date
WO2021202780A2 (en) 2021-10-07
EP4127722A4 (en) 2024-05-01
JP2023519931A (ja) 2023-05-15
US20230149415A1 (en) 2023-05-18
WO2021202780A3 (en) 2021-11-11
CN115769077A (zh) 2023-03-07
MX2022012181A (es) 2023-01-30
AU2021249111A1 (en) 2022-10-20
EP4127722A2 (en) 2023-02-08
KR20230017167A (ko) 2023-02-03

Similar Documents

Publication Publication Date Title
US20230149415A1 (en) Methods and compositions for treating cancer
Amaral et al. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents
Jörger et al. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
Tong et al. A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma
EP2981252A1 (en) Methods of treating diseases characterized by excessive wnt signalling
KR20180035905A (ko) Bet 브로모도메인 억제제에 대한 저항성의 메카니즘
Oh et al. NQO1 regulates cell cycle progression at the G2/M phase
EP3513192B1 (en) Cell death biomarker
WO2012177925A1 (en) Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
Araki et al. Targeting pre-mRNA splicing in cancers: roles, inhibitors, and therapeutic opportunities
Ladd et al. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations
Fujita et al. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells
US20220356494A1 (en) Methods and compositions for treating cancer
Lu et al. [Retracted] Brusatol Inhibits Proliferation and Metastasis of Colorectal Cancer by Targeting and Reversing the RhoA/ROCK1 Pathway
Zhao et al. Supramolecular nanodrug targeting CDK4/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma
Zhou et al. BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells
Qin et al. The long non-coding RNA OTX2-AS1 promotes tumor growth and predicts response to BCL-2 inhibition in medulloblastoma
Ferreira et al. The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies
Lewis et al. RNA Splicing as a Therapeutic Target in Cancer
US20230073494A1 (en) Compositions and methods for generating synthetic lethality in tumors
WO2021206633A1 (en) Methods and compositions for treating liver cancer
US20220218708A1 (en) Methods for treating smarcb1 deficient cancer or pazopanib resistant cancer
Wu et al. Roles of deubiquitinases in urologic cancers
HK40089758A (zh) 用於治疗癌症的方法和组合物
Nazarov et al. Effects of n-Myc and c-Myc on the expression of p53 family members and their transcriptional targets in human neuroblastoma cells

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250321

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250328

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250328

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250328

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250331

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250430

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250430

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250430

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250520